ST美訊(600898.SH):控股子公司為公司銀行授信提供3000萬元擔保
格隆匯7月22日丨ST美訊(600898.SH)公吿,因業務發展需要,公司與興業銀行上海五角場支行簽訂額度授信合同,授信金額為4000萬元(敞口額度3000萬元),期限為2021年6月1日至2022年5月22日。具體額度業務種類包括但不限於流動資金貸款、銀行承兑匯票、信用證及項下融資。
據悉,公司控股子公司國美通訊(浙江)有限公司為上述銀行授信提供3000萬元的連帶責任保證並簽訂《最高額保證合同》。
截止2021年6月30日,公司對外擔保餘額為人民幣11,260萬元,佔公司最近一期經審計歸屬於母公司所有者的淨資產的901.90%,全部為對全資子公司及控股子公司提供的擔保。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.